GREEN ANDREW M sold $287K of AORT

Artivion Inc. (AORT) reported Q2 2026 revenue growth of 11% to $125.8M, driven by its aortic arch portfolio. However, it posted a net loss of $13.5M, reversing from a profit a year earlier. The company completed the Endospan acquisition and received FDA approval for AMDS. Despite growth, profitability declined, and guidance was reiterated without an increase.

Artivion (AORT) reported Q2 2026 revenue of $125.76M, up from $112.97M a year earlier, but shifted from net income to a loss of $13.51M. H1 2026 revenue rose to $242.09M, but the company moved to a net loss of $12.09M. The company projects $619.8M revenue and $44.7M earnings by 2029, requiring 10.6% yearly revenue growth.

Artivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.

Artivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.

Artivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.

Artivion (NYSE:AORT) reported Q2 CY2026 revenue of $125.8 million, up 11.3% year over year and 4.4% above Wall Street estimates, according to the company. Non-GAAP EPS was $0.13, clearing consensus. The company guided full-year revenue to about $488 million and expects EPS around $0.54.